Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals

In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 ... Read More